A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

• Has nonsquamous NSCLC (Stage IIIB, Stage IIIC) not eligible for curative resectionor chemoradiation or Stage IV: M1a, M1b, or M1c

• If human immunodeficiency virus (HIV) positive, must have well controlled HIV onantiretroviral therapy (ART)

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

• Has diagnosis of small cell lung cancer or, for mixed tumors, presence of small cellelements

• Has active inflammatory bowel disease requiring immunosuppressive medication orprevious clear history of inflammatory bowel disease (e.g., Crohn's disease,ulcerative colitis, or chronic diarrhea)

• Has uncontrolled, significant cardiovascular disease or cerebrovascular disease

• Has a gastrointestinal disorder affecting absorption

• Is HIV positive and has a history of Kaposi's sarcoma and/or MulticentricCastleman's Disease

• Has received prior systemic anticancer therapy for their advanced or metastaticNSCLC

• Has known additional malignancy that is progressing or has required active treatmentwithin the past 3 years

• Has known active central nervous system (CNS) metastases and/or carcinomatousmeningitis

• Has active autoimmune disease that has required systemic treatment in the past 2years

• History of (noninfectious) pneumonitis/interstitial lung disease that requiredsteroids or has current pneumonitis/interstitial lung disease

• Has active infection requiring systemic therapy except those specified by protocol

• Has history of stem cell/solid organ transplant

• Has not adequately recovered from major surgery or has ongoing surgicalcomplications